Last updated: 2026-09-07 22:55:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SCYNEXIS, Inc. (SCYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.32, with a market capitalization of $52.73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.53 to $10.48. This page covers its latest market performance, valuation, price trends and company information.
$52.73M | |
$5.36 | |
$1,200.00 | |
$3.53 | |
$5.35 | |
54.87K | |
136.84K | |
-- | |
$10.48 | |
$3.53 | |
-- | |
-- |
SCYNEXIS, Inc. (SCYX) last closed at $5.35 as of 2026-09-04 23:31:00, unchanged from the previous close of $5.35.
During the latest regular trading session, SCYX traded between $3.53 and $1,200.00, with a volume of 54.87K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, SCYNEXIS, Inc. (SCYX) moved from $5.52 to $5.32, representing a decline of 3.70% ($0.20).
The stock traded between $5.03 and $5.70 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 55.92 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 25.7%
SCYX is currently trading at $5.32, placing it 25.7% of the way from its 52-week low of $3.53 to its 52-week high of $10.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SCYNEXIS, Inc. (SCYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.